Drugs that contain Dextroamphetamine

1. List of Xelstrym drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US8591941 NOVEN PHARMS INC Transdermal drug delivery device including an occlusive backing
Oct, 2025

(2 years from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(2 years from now)

US9456993 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(10 years from now)

US9474722 NOVEN PHARMS INC Compositions and methods for transdermal delivery of amphetamine
Oct, 2033

(10 years from now)

US11559501 NOVEN PHARMS INC Transdermal amphetamine compositions with low levels of carbamate
Jan, 2042

(18 years from now)

Do you want to check out XELSTRYM patents from before 2022?
Exclusivity Exclusivity Expiration
New Product (NP) Mar 22, 2025

Market Authorisation Date: 22 March, 2022

Treatment: A method of treating attention deficit hyperactivity disorder by administering a transdermal composition containing amphetamine

Dosage: SYSTEM;TRANSDERMAL

More Information on Dosage

XELSTRYM family patents

26

United States

3

Spain

3

Canada

3

Taiwan

3

Argentina

3

European Union

2

Mexico

1

Hong Kong

1

Peru

1

Japan

1

Australia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic